1. In a method for treating a human suffering from a disease or
disorder comprising administering a therapeutically effective amount of a whole
glycosylated recombinant human, chimeric or CDR2-grafted or bispecific
antibody effective in treating said disease or disorder in said human, wherein the
improvement comprises an antibody glycosylated by a chinese hamster ovary cell.
9. Claim 1 of the '404 patent reads as follows:
1. In a method for treating a human suffering from a T-cell mediated
disorder comprising administering a therapeutically effective amount of a whole
glycosylated recombinant human, chimeric, CDR-grafted or bispecific antibody
effective in treating said disorder, wherein the improvement comprises an
antibody glycosylated by a Chinese hamster ovary cell.
10. Claim 1 of the '405 patent reads as follows:
1. In a method for treating a human suffering from cancer by
administering a therapeutically effective amount of a whole glycosylated
recombinant human, chimeric, CDR grafted or bispecific antibody effective in
treating said cancer, wherein the improvement comprises an antibody
glycosylated by a Chinese hamster ovary cell.
11. Claims 53, 55, and 56 of the '611 application read as follows:
53. In a method for treating a human suffering from a disease
comprising administering a glycosylated recombinant human, chimeric, hybrid,
altered or univalent antibody to said human in an amount effective in treating said
disease in said human, wherein the improvement comprises administering an
antibody glycosylated by a Chinese hamster ovary cell to said human.
55. In a method for treating a human suffering from an attack by a
substance or organism comprising administering a glycosylated recombinant
human, chimeric, hybrid, altered, or univalent antibody to said human in an
amount effective in treating said attack of said human, wherein the improvement
comprises administering an antibody glycosylated by a Chinese hamster ovary
cell to said human.
56. A method for treating a subject suffering from an attack by a
substance or organism, comprising administering an antibody which binds to said
substance or organism in an amount effective to combat said attack, wherein said
antibody is a recombinant human, chimeric, hybrid, altered, or univalent antibody
expressed by a Chinese hamster ovary cell.
2 We understand “CDR” to be “complementarity determining regions.”
-5-
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007